BioPharmSignal logoBioPharmSignal

Biotech News

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

CytomX Therapeutics, Inc. (CTMX)CytomX Therapeutics, Inc.Earnings

- Varsetatug masetecan (Varseta-M) granted FDA Fast Track designation for relapsed/refractory metastatic colorectal cancer - - Phase 1 monotherapy data update in metastatic colorectal cancer (mCRC) expected in January 2027 - - Phase 1 study in combination with bevacizumab in 3L+ mCRC ongoing.

Related news

CTMXCytomX Therapeutics, Inc.2026-10-29 12:00 EST

CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

ELVNEnliven Therapeutics2026-11-05 21:05 EST

Enliven Therapeutics Reports Third Quarter 2026 Financial Results and Provides a Business Update

FATEFate Therapeutics2026-11-05 12:00 EST

Fate Therapeutics Reports Third Quarter 2026 Financial Results and Business Updates

RLAYRelay Therapeutics2026-10-28 20:12 EST

Relay Therapeutics to Announce Third Quarter 2026 Financial Results and Corporate Highlights on November 4, 2026

NRIXNurix Therapeutics2026-10-12 20:05 EST

Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update

KYMRKymera2026-10-22 20:01 EST

Kymera Therapeutics to Report Third Quarter 2026 Financial Results on October 29, 2026

LYELLyell Immunopharma2026-11-04 21:05 EST

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2026

RVMDRevolution Medicines2026-11-04 21:02 EST

Revolution Medicines Reports Third Quarter 2026 Financial Results and Update on Corporate Progress

IDYAIDEAYA Biosciences2026-11-03 11:00 EST

IDEAYA Biosciences Reports Financial Results for the Third Quarter 2026 and Provides a Business Update

COGTCogent Biosciences2026-11-05 21:02 EST

Cogent Biosciences Reports Recent Business Highlights and Third Quarter 2026 Financial Results

View all latest news

CytomX Therapeutics, Inc.

Conditionally Activated Biologics CytomX Therapeutics develops masked PROBODY therapeutics designed to become active in the tumor microenvironment. The approach aims to improve the therapeutic window of potent antibodies and antibody-drug conjugates. Varsetatug Masetecan Varsetatug masetecan, or Varseta-M, is an EpCAM-directed PROBODY...

Recent company news

CTMXCytomX Therapeutics, Inc.2026-11-05 21:15 EST

CytomX Therapeutics Announces Q3 2026 Financial Results and Provides Business Update

CTMXCytomX Therapeutics, Inc.2026-11-02 13:00 EST

CytomX Therapeutics to Present at Upcoming November Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-10-29 12:00 EST

CytomX Therapeutics to Report Third Quarter 2026 Financial Results on November 5, 2026

CTMXCytomX Therapeutics, Inc.2026-09-01 12:00 EST

CytomX Therapeutics to Present at Upcoming September Investor Conferences

CTMXCytomX Therapeutics, Inc.2026-08-27 12:00 EST

CytomX Therapeutics Announces FDA Fast Track Designation for Varsetatug masetecan (“Varseta-M”) for Relapsed/Refractory Metastatic Colorectal Cancer (R/R mCRC)

Stock data

Close
2.14 USD
Market cap
687.94M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States